ANRO Latest Headlines

ANRO’s $50 Million Financing Signals Aggressive Push in Treatment-Resistant Depression Research

Market Chameleon (Mon, 20-Oct 10:29 AM)

Alto Neuroscience Secures $50 Million to Fast-Track Key Depression Drug: Here’s What Stands Out

Market Chameleon (Mon, 20-Oct 7:54 AM)

FDA Fast Track for ALTO-101 Spotlights Alto Neuroscience’s Push Toward a Novel Schizophrenia Treatment

Market Chameleon (Fri, 3-Oct 10:29 AM)

FDA Fast Track Designation Positions ANRO’s ALTO-101 as a Potential Game-Changer for Schizophrenia Cognitive Impairment

Market Chameleon (Fri, 3-Oct 8:04 AM)